Published June 2001 | Version v1
Report Open

Experience with radioimmunotherapy and radio-peptide therapy

  • 1. St. Bartholomew's and Royal London School of Medicine and Dentistry, Queen Mary and Westfield College, University of London (United Kingdom)

Description

The expression of antigens and peptides on the cell surface of target cells has provided the use of monoclonal antibodies and peptides for experimental tumour therapy. Several studies using monoclonal antibodies (such as the anti-ovarian cancer monoclonal antibody 90Y-HMCF1, the anti-CEA monoclonal antibody PR1A3 (ICRF), the anti-CD20 monoclonal antibody and the 90Y-labelled lanreotide peptide are shortly discussed and highlighted regarding their clinical potential to treat cancer. (author)

Files

32046368.pdf

Files (44.4 kB)

Name Size Download all
md5:5d8b485b0e413c265a26d46e3a1e92b5
44.4 kB Preview Download
Part of:
Therapeutic applications of radiopharmaceuticals. Proceedings of an international seminar

Additional details

Publishing Information

Imprint Title
Therapeutic applications of radiopharmaceuticals. Proceedings of an international seminar
Imprint Pagination
354 p.
Journal Page Range
p. 49-50
ISSN
1011-4289
Report number
IAEA-TECDOC--1228

Conference

Title
International seminar on therapeutic applications of radiopharmaceuticals
Dates
18-22 Jan 1999
Place
Hyderabad (India)

Optional Information